127 results about "Lipid molecule" patented technology

The invention discloses a circRNA nano delivery system capable of reversing nucleus pulposus progenitor cell senescence and a preparation method and application of the circRNA nano delivery system. The circRNA nano delivery system comprises: a) Klotho circRNA, and b) a liposome, and the liposome comprises a vascular peptide vasculotide, an ionizable lipid molecule, a phospholipid, a PEG lipid, and a steroid. The invention also provides application of the circRNA nano delivery system capable of reversing nucleus pulposus progenitor cell senescence in preparation of drugs for treating intervertebral disc degeneration. The invention provides liposome particles (Vas-Klotho-LNP) which have targeted NPPCs and wrap circRNA, Klotho circRNA is efficiently introduced into the NPPCs through Tie2 agonist peptide, so that rejuvenation of the NPPCs is promoted, ECM synthesis is promoted, and regeneration and repair of intervertebral discs are synergistically promoted in vivo and in vitro.

The invention discloses a method for improving the survival rate of probiotics based on cell membrane regulation and control. The method comprises the following steps: adding a lipid component in a probiotic culture process and / or adding the lipid component as a protective agent after probiotic culture, the lipid component added in the probiotic culture process comprises cytidine diphosphate diacylglycerol and / or stearic acid; the lipid component added as the protective agent after culture comprises cardiolipin and / or oleic acid. The method breaks through the research category of a traditional optimized freeze drying process (such as a protective agent and parameters), and key lipid molecules directly related to resistance are screened out through a lipidomics means and establishment of a screening method of stress resistance related lipid molecules; through a dual mode of supplementing key lipid components and precursor substances thereof, the tolerance of the strain is improved from the metabolic level, and the freeze-drying resistance and the survival rate of the strain are remarkably improved.

The invention provides a carrier material for supporting a protein drug. The carrier material comprises an inner core, a calcium carbonate coating layer coating the inner core and a polyethylene glycol-polyglutamic acid diblock copolymer chain segment anchored on the coating layer. The intracellular protein delivery carrier provided by the invention can effectively support various metal ions and protein drugs with the Fenton / Fenton-like reaction catalysis effect, and after the intracellular protein delivery carrier is endocytosed by cells, the protein drugs, calcium ions and the metal ions with the Fenton / Fenton-like reaction catalysis effect are released; metal ions can catalyze hydrogen peroxide in the endosome / lysosome to generate hydroxyl radicals with high oxidation activity, lipid molecules are oxidized, and a lysosome membrane is destroyed; the released calcium ions can cause mitochondrial calcium overload, improve the level of hydrogen peroxide in cells, promote generation of hydroxyl radicals in endosome / lysosome and damage of membranes of the hydroxyl radicals, induce efficient rupture of the endosome / lysosome and deliver protein drugs into cytoplasm so as to play the functions of the protein drugs.

The invention relates to the field of biological medicine, and discloses application of LPC, PC and AA in children sepsis diagnosis and prognosis product development. According to the invention, a high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS / MS) technology is used, plasma samples of a child sepsis patient and a healthy control group are compared, the relationship between lipidome change and pSOFA score is analyzed, and specific lipid molecules closely related to disease severity and prognosis are identified. According to the invention, the following lipid molecules are highlighted as key biomarkers: lysophosphatidylcholine (LPC), phosphatidylcholine (PC) and arachidonic acid (AA). The change of the lipid molecules is closely related to the physiological state of a child sepsis patient, and the lipid molecules can be used for early diagnosis and evaluation of the state of the child sepsis, so that the treatment effect and the accuracy of prognosis evaluation are improved, and a new treatment strategy and a new management method are provided for clinic.

The present invention relates to ionizable lipid nanoparticles (LNPs) including at least one lipid molecule comprising a thiourea moiety linked to a functional moiety. The ionizable lipid nanoparticles (LNPs) including at least one lipid molecule comprising a thiourea moiety linked to a functional moiety, disclosed herein, are useful in delivering an agent to a cell or in transfecting a cell, especially for gene therapy or for gene editing.

A vaccine adjuvant, and a preparation method therefor and a use thereof. The vaccine adjuvant is a MA105 immunologic adjuvant, and comprises (1) QS-21:50 μg / ml to 300 μg / ml; (2) Poly I:C: 400 μg / mL to 3000 μg / mL; and (3) lipid molecules constituting a vector, the vector being a mixture of a cationic liposome and a neutral liposome.

The invention discloses a salmonella typhimurium EN-VNP strain based on flagellin and LPS attenuation as well as a preparation method and application of the salmonella typhimurium EN-VNP strain, and particularly relates to the technical field of biology. The bacterial strain is formed by sequentially knocking out or silencing flagellin genes fliC and fljB, a phosphoethanolamine transferase gene eptA, a 4-amino-4-deoxy-L-arabinose transferase gene arnT and phosphotransferase yeiU on the basis of a salmonella VNP 20009 bacterial strain, and knocking in or overexpressing a phosphotransferase gene lpxE. The salmonella typhimurium EN-VNP strain disclosed by the invention has relatively high safety, the attenuated strain does not contain flagellin, and a lipid A molecule of LPS only retains one phosphate group, so that the safety of the strain is improved, and the strain is more suitable for serving as a vaccine and a drug delivery carrier.

The invention relates to an auxiliary lipid molecule containing a tocopherol structure, a lipid nanoparticle containing the auxiliary lipid molecule and application of the auxiliary lipid molecule. Specifically, the invention provides an auxiliary lipid molecule containing tocopherol and a derivative structure thereof as shown in a formula (1), a lipid nanoparticle containing the auxiliary lipid molecule, and a preparation method and application of the auxiliary lipid molecule. Compared with auxiliary lipid molecules conventionally used in the field, the lipid nanoparticles prepared from the auxiliary lipid molecules shown in the formula (1) can significantly improve the delivery efficiency and expression of nucleic acid. # imgabs0 #

The invention discloses a preparation method and application of bioactive lipid and lipid nanoparticles thereof. The bioactive lipid molecule is formed by bonding long-chain fatty acid (LCFA) with different chain lengths with two functional small molecules, namely phenylboronic acid pinacol ester (PBAP) and Tempol (Tpl) respectively, so that two types of lipid molecules, namely PBAP-LCFA and Tpl-LCFA, with anti-inflammatory activity are constructed. The lipids are used as functional components, and the anti-inflammatory lipid nanoparticles with good biocompatibility, including PLP, TLP and TPLP, can be prepared through a film dispersion method. The lipidoid and the lipid nanoparticles are simple and convenient in preparation process, controllable in structure and function and easy for large-scale production, and have treatment potential in various acute and chronic inflammatory diseases. In an animal model, the lipid nanoparticles have remarkable curative effects on acute peritonitis, acute lung injury, acute hepatic failure, asthma and other diseases. Besides, the lipid bilayer structure of the TPLP can efficiently entrap hydrophilic / hydrophobic drugs, can synergistically deliver treatment drugs while exerting the anti-inflammatory effect of the TPLP, and realizes a synergistic combined treatment strategy for chronic lung inflammation and other diseases.

The invention relates to a lipid molecule, and a composition and application thereof. The core structure of the lipid-like molecule covers a two-dimensional plane structure and a plurality of three-dimensional structures, and endows the LNP with adjustable membrane tissue characteristics and intracellular transport behaviors, so that a new strategy of adjusting delivery performance from the structural level is realized. In addition, part of the ionizable lipid is introduced into a fluorine substituent group, so that the internal hydrophobic interaction and colloidal stability of the LNP are improved, and the in-vivo delivery persistence is prolonged. The invention also provides a component-simplified LNP delivery system based on programmable regulation and control of ionizable lipid chemical bonds, which is different from the traditional strategy of needing to remove hepatic tropism components (such as cholesterol) or additionally introduce targeted regulation and control lipid (a fifth component) to realize organ targeting. Selective delivery of organs such as liver, spleen, lung, pancreas and the like can be realized under the condition of retaining cholesterol only by changing the type of a chemical bond between an aliphatic chain and a core structure in the ionizable lipid.

The present invention discloses a lipid prodrug nanoassembly based on dynamic covalent chemistry, and its preparation method and application, which belong to the fields of dynamic binding chemistry and nanotechnology. The present invention designs a dynamic covalent chemical lipid nano drug delivery system, which is mainly obtained by self-assembly of lipid molecules with a hydrophilic head, a hydrophobic tail and a dynamic covalent side chain. The molecule has an o-diphenol side chain group and can be combined with anti-cancer, antibacterial and antifungal drugs, and has good anti-tumor and antibacterial effects. The present invention constructs a lipid drug delivery platform through dynamic covalent chemistry for the first time, which has the advantages of responsiveness, fixed point, on-demand release, etc. in terms of function. It combines a variety of drugs such as anti-cancer, antibacterial and antifungal drugs with lipid molecules through dynamic covalent chemistry to improve the therapeutic effect of drugs.

The present invention provides novel ionizable cationic lipid molecules, lipid nanoparticles composed of these lipid molecules, neutral lipid molecules, cholesterol-like lipid molecules, and PEGylated lipid molecules, and compositions containing these lipid nanoparticles. These lipid nanoparticles, as delivery vehicles for active ingredients, offer advantages such as small and uniform particle size, high encapsulation efficiency, and high cell transfection efficiency, making them particularly suitable for delivering nucleic acid molecules (e.g., mRNA).

The invention relates to a method for extracting and detecting lipid in liquid raw milk, and provides a method for extracting and detecting lipid in liquid raw milk by verifying and preferably selecting a Bligh-Dyer method for extracting lipid in liquid raw milk and optimizing chromatography and mass spectrometry conditions, so as to improve the separation and identification capability of complex lipid molecules. And the detection sensitivity and stability are obviously improved.

This invention discloses a cationic lipid molecule based on lipoic acid derivatives for mRNA delivery, its preparation method, and its uses. The cationic lipid molecule is prepared by reacting lipoic acid with a hydrophilic amine, wherein the hydrophilic amine is one of 4A1, 5A1, or 6A2. The cationic lipid molecule synthesized in this invention contains a protonated nitrogen atom that can bind to negatively charged nucleic acids and form highly stable nanoparticles with polyethyleneimine (PEI), thus improving nucleic acid loading and demonstrating its excellent application in mRNA delivery.

The present disclosure describes a lipid-polymer hybrid nanoparticle and a method of synthesizing such a nanoparticle or a composition containing such a nanoparticle. These nanoparticles are made from a biodegradable polymer-based micellar core surrounded by a lipid-based shell, wherein a majority of the agent is present on the inner periphery of such nanoparticles due to physical adhesion to lipid molecules. Only a small amount of medicament is encapsulated in the micelle core. Thus, the lipid-based shell becomes the primary excipient part of the nanoparticle, and the core containing the biodegradable polymer becomes the secondary excipient part of the nanoparticle.

The invention belongs to the technical field of biological medicine, and particularly provides a branched polyamidoamine lipid molecule, a nucleic acid targeted delivery system based on the branched polyamidoamine lipid molecule and a preparation method of the branched polyamidoamine lipid molecule, the branched polyamidoamine lipid molecule and the nucleic acid targeted delivery system based on the branched polyamidoamine lipid molecule are prepared by synthesizing branched lipid molecules PAMAM / S, PAMAM / Se and PAMAM / C with reduction potential adjustable groups S-S, Se-Se and C-C, optimizing the formula proportion of PAMAM / S: DOPC: Chol: DMG-PEG in LNP, and combining a microflow control preparation technology to obtain the branched polyamidoamine lipid molecule with the particle size of 80 nm and PDIlt; and 0.2 of stable nanoparticles. The delivery system specifically targets liver Kupffer cells, the EGFP transfection efficiency reaches 47.1% and is remarkably higher than that of traditional LNP, the cytotoxicity and immunogenicity are low, and the delivery system is suitable for development of mRNA vaccines and gene therapy drugs.

The invention relates to a novel analysis method for carrying out lipid gas phase dissociation by adopting pulse extreme ultraviolet laser and characterizing a lipid molecular structure by analyzing dissociated fragment ions through mass spectrometry. A lipid sample enters a gas phase through electrospray ionization, then lipid molecules with accurately selected mass are efficiently excited and dissociated by adopting extreme ultraviolet laser to generate fragment ions with sequence and structural characteristics, and finally the fragment ions are detected through mass spectrum. According to the method, efficient extreme ultraviolet light dissociation of lipid molecules can be achieved, structural characteristics such as head groups, sn positions, double bond positions and cis-trans isomerism of the lipid molecules can be accurately determined through fragment ion spectrogram analysis, and accurate identification and distinguishing of complex lipid isomers are achieved.

The invention discloses a post-AMI heart failure oxidized lipid screening method based on solid phase extraction, LC-MS / MS and AI. The method comprises the steps of blood sample pretreatment, solid phase extraction and purification, LC-MS / MS detection and AI model screening. According to the method, high-sensitivity qualitative and quantitative detection of oxidized lipid is realized through optimized LC-MS / MS parameters, and key oxidized lipid molecules and risk levels of heart failure after AMI emergency treatment blood supply reconstruction can be quickly and accurately screened in combination with a trained random forest AI model; the kit solves the problems that in the prior art, trace oxidized lipid detection sensitivity is low, specificity is poor, and heart failure risk screening lags, has the advantages of being high in detection efficiency, good in accuracy and high in practicability, can provide a scientific basis for early warning and intervention of clinical heart failure after AMI, and has high clinical application value.

An inference device includes a processor; and a memory storing program instructions that cause the processor to acquire input data including at least chemical structure information on a lipid molecule; input the input data newly acquired into a learned model generated by performing a learning process on a learning model that associates input data including at least chemical structure information on a lipid molecule with information indicating distribution or behavior of an active ingredient encapsulated in a particle containing the lipid molecule in a living organism, to infer information indicating distribution or behavior in the living organism, associated with the newly acquired input data; and output, based on the inferred information, information indicating distribution or behavior in either or both of a predetermined tissue and cell in the living organism or information indicating behavior in any one or more of tissue, blood, or urine.

The present invention relates to a long chain alkyl esteramine lipid compound as shown in Formula I, preparation method therefor as well as use thereof in nucleic acid delivery, the long chain alkyl esteramine lipid compound provided by the present invention has an excellent encapsulation rate and delivery effect as a lipid molecule in delivering disease treatment or preventive agents, showing lower toxicity and certain tissue distribution characteristics, and providing a basis of more selections for delivering disease therapeutic or prophylactic agents.

The invention discloses an imidazolyl lipid assembly as well as a preparation method and application thereof, and relates to the technical field of biomedical materials. The preparation method comprises the following steps: mixing diphenyl phosphate, alcohol and pyridine, and heating for reaction to obtain alkyl phosphate; mixing N, N-diethylethylenediamine, 5-imidazole formaldehyde and a solvent, carrying out a heating reaction in a protective atmosphere, then adding the alkyl phosphate, and continuing the heating reaction to obtain an imidazolyl lipid molecule; dissolving the imidazolyl lipid molecules in an organic solvent to obtain a mother solution; the imidazolyl lipid assembly is obtained from the mother liquor through a film hydration method. The imidazole-based lipid assembly constructed by the invention can utilize the imidazole group to destroy the normal structure of bacteria under the condition of no antibiotic load, and utilizes the catalytic action of the imidazole group to complete the destroy of a biological membrane matrix and an inflammation activation medium, so that the synergism of antibiosis and anti-inflammation is realized, and the imidazole-based lipid assembly has the effect of buffering local acidic pH.

The invention relates to an ionizable lipid molecule containing an arginine structure, a lipid nanoparticle containing the ionizable lipid molecule and application of the ionizable lipid molecule. Specifically, the invention provides an ionizable lipid molecule containing arginine and a derivative structure thereof as shown in a formula (1), a lipid nanoparticle containing the ionizable lipid molecule, and a preparation method and application of the ionizable lipid molecule. Compared with ionizable lipid molecules conventionally used in the field, the lipid nanoparticles prepared from the ionizable lipid molecules shown in the formula (1) can achieve high-efficiency delivery and expression of nucleic acid.

The invention belongs to the field of myocardial infarction diagnosis and research, and particularly relates to a serum lipid biomarker for predicting the recurrence risk of myocardial infarction and application of the serum lipid biomarker. The invention discloses a serum lipid biomarker for predicting the recurrence risk of myocardial infarction. The serum lipid biomarker for predicting the recurrence risk of myocardial infarction is PI (18: 2), PI (16: 0), TG (20: 2), PC (22: 4) and PI (22: 6). According to the method, through lipid deconstruction analysis with higher resolution, lipid molecules of a specific chain structure closely related to the PRMI risk can be identified, and more accurate prediction of the recurrence risk is realized. The deconstructed lipid molecular marker provided by the invention has higher specificity and reliability in clinical application, not only can make up for the defects of the traditional lipid marker, but also provides a brand new technical means and application prospect for early recognition and individualized intervention of AMI postoperative recurrence risk.

Provided are a peroxide-containing liposome, a preparation method therefor, and use thereof. The peroxide-containing liposome is a spherical vesicle having a double-layer membrane structure and formed by lipid molecules containing one or more peroxy groups, and the lipid molecules contain carbon-carbon double bonds. The peroxide-containing liposome can be obtained by mixing peroxide-containing lipid molecules with an aqueous system, wherein the peroxide-containing lipid molecules are obtained by reacting unsaturated lipid molecules containing -CH=CH- and / or -C≡C- with an additive in the presence of oxygen and a solvent, and the additive is selected from one or more of lipoxygenase, an oxidation catalyst, and an oxidizing agent. By means of in-vitro experiments in cells and in-vivo experiments in animals, it is found that the peroxide-containing liposome can kill tumor cells and can be used as a sensitizing agent in combination with other tumor treatment methods to effectively improve the therapeutic effect on tumors, thus having good application prospects in resisting tumors.

Provided is a novel cell capture method.　The present technology provides a bioparticle capture method, etc., in which at least a capture step, for capturing a bioparticle having a lipid membrane using a lipid-molecule-modified nucleic acid having a branched structure and a plurality of modified lipid molecules, is performed, and the distance from a branch point of the branched structure to a hydroxyl group that binds a lipid molecule is 3 Å or more.

The present invention belongs to the technical field of biochemistry, and specifically relates to a phosphoramidite lipid molecule and a use thereof in an RNAi molecule. In the present invention, a series of lipid molecules containing phosphoramidite are prepared and reacted with oligonucleotides to prepare an RNAi molecule. The RNAi molecule can effectively target extrahepatic tissues, while not interfering with the effect of inhibiting a target gene. The lipid molecule prepared in the present invention has good prospects in extrahepatic delivery vectors, and the RNAi molecule prepared in the present invention has important value for the research and development and clinical application of RNAi drugs.

The application discloses preparation and application of lipid molecules and compositions thereof for delivering active ingredients, and relates to the field of biological medicine. The novel lipid molecules comprise general formula (I), (II) or (III): and can be used for delivering active ingredients (such as nucleic acids, polypeptides, proteins) to cells and / or organs. Embodiments of the application provide nucleic acid-lipid nanoparticle compositions of various novel lipid molecules, and a lipid nanoparticle delivery system composed of the same is used for delivering mRNA; the delivery efficiency is superior to that of the currently marketed product DLin-MC3-DMA at both a cell level and an animal level, and the lipid molecules can be used as a novel method for delivering nucleic acid drugs and promote development of nucleic acid drugs.

This invention provides a lipid compound, its preparation method and application, and a pharmaceutical composition, belonging to the pharmaceutical field. Through innovative design of the chemical structure of lipid molecules, particularly by specific modification of the hydrophilic head group and / or hydrophobic tail structure, this invention enables specific expression of mRNA in the liver, effectively avoiding off-target effects in non-target organs, and has significant scientific value and broad application prospects.